Advances in therapy · 2018
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
СтатьяОбзорConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kalra Sanjay, Atkin Stephen, Cervera Antonio, Das Ashok Kumar, Demir Ozgur, Demir Tevfik, Fariduddin Md, Vo Khoa Tuan, Ku Bon Jeong, Kumar Ajay, Latif Zafar A, Malek Rachid, Matawaran Bien J, Mehta Roopa, Tran Nam Quang, Panelo Araceli, Ruder Sundeep, Saldana Joel Rodriquez, Shaikh Khalid A, Shakya Amit, Shrestha Dina, Unnikrishnan A G
Аннотация
Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4-5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.